Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515228 | 0.88 | KDM4E (0.45) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL27160143 | 0.86 | ALDH1A1 (0.43) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL6408637 | 0.85 | KEAP1 (0.58) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL5319576 | 0.84 | KEAP1 (0.47) | KDM4ESMN1; SMN2KEAP1ALDH1A1HPGD | |
| SCHEMBL235080 | 0.83 | KDM4E (0.65) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL11333121 | 0.81 | TDP1 (0.41) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL11270767 | 0.81 | HRH3 (0.40) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL2595940 | 0.80 | KDM4E (0.46) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL21623672 | 0.80 | KDM4E (0.46) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL5345779 | 0.80 | KDM4E (0.46) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1692112-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-1594849-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2007-07-04 | — | — | EP | claimed |
| US-20070149500-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | claimed |
| EP-1692112-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-08-23 | — | — | EP | claimed |
| EP-1686120-A2 | Methods and compositions utilizing quinazolinones | Cytokinetics, Inc. (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1594849-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20050234037-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2005-10-20 | — | — | US | claimed |
| WO-2005061460-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | WO | claimed |
| WO-2004064741-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2001030768-A9 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS INC (US) | 2002-08-15 | — | — | WO | claimed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | claimed |
| US-8658656-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8470838-B2 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | CYTOKINETICS, INCORPORATED (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-6562831-B1 | Inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases | CYTOKINETICS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6545004-B1 | Treating cellular proliferative diseases and disorders associated with KSP kinesin activity. | CYTOKINETICS, INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149500-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | KDM4E 1780/4885SMN1; SMN2 2221/4885KEAP1 1859/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KDM4E 1983/4885SMN1; SMN2 2102/4885KEAP1 2271/4885 |
| US-20050234037-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | KDM4E 1780/4885SMN1; SMN2 2221/4885KEAP1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.